IP Library Granted Patent US 9,090,879
Granted Patent B2
US 9,090,879 · App. 14/364,756 · Granted Jul 28, 2015

Bioengineered allogeneic blood vessel

Inventors: Suchitra Sumitran-Holgersson (Sweden, SE); Michael Olausson (Sweden, SE)
Assignee: NOVAHEP AB
C12N5/0691A61K35/14A61K35/28A61K35/34A61K35/44A61K35/545A61L27/3625A61L27/3808A61L27/3826A61L27/3834A61L27/3886A61L27/507A61F2/062A61K2035/124C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,879
App. No.
14/364,756
Granted
Jul 28, 2015
Kind
B2
Abstract

The present invention relates to methods for recellularization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.

Claims (24)

1. A method of recellularizing a blood vessel comprising introducing whole blood comprising endothelial cells, smooth muscle cells, and/or progenitor cells for endothelial and smooth muscle cells to the lumen of a decellularized blood vessel, and culturing said cells on the decellularized blood vessel, thereby recellularizing the blood vessel.

2. The method of claim 1 , wherein said introducing the whole blood to the decellularized blood vessel is by injection or perfusion.

3. The method of claim 2 , further comprising culturing said cells by perfusion of endothelial cell medium and/or smooth muscle cell medium.

4. The method of claim 3 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are in alternation.

5. The method of claim 4 , wherein said perfusion of said medium in alternation is repeated at least twice.

6. The method of claim 1 , wherein said culturing the cells on the decellularized blood vessel results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.

7. The method of claim 6 , wherein said endothelial cells line the inner lining or the lumen of the decellularized blood vessel and said smooth muscle cells migrate to the walls or are present over the middle and outer layers of the decellularized blood vessel.

8. The method of claim 7 , wherein said endothelial cells express VE-cadherein, AcLDL, vWF or CD31.

9. The method of claim 7 , wherein said smooth muscle cells express smooth muscle actin or vimentin.

10. The method of claim 1 , wherein said blood vessel is vein or artery.

11. A method for providing a blood vessel graft to a patient comprising:

a. delivering patient-derived whole blood comprising endothelial cells, smooth muscle cells, and/or progenitor cells for endothelial and smooth muscle cells to the lumen of a decellularized blood vessel;

b. culturing said cells on the decellularized blood vessel, thereby recellularizing the blood vessel; and,

c. transplanting the recellularized blood vessel into the patient.

12. The method of claim 11 , wherein said decellularized blood vessel is from an allogeneic donor.

13. The method of claim 11 , wherein said introducing the patient-derived whole blood to the decellularized blood vessel is by injection or perfusion.

14. The method of claim 13 , further comprising culturing said cells by perfusion of endothelial cell medium and/or smooth muscle cell medium.

15. The method of claim 14 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are in alternation.

16. The method of claim 15 , wherein said perfusion of said medium in alternation is repeated at least twice.

17. The method of claim 11 , wherein said culturing on the decellularized blood vessel results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.

18. The method of claim 17 , wherein said endothelial cells line the inner lining or the lumen of the decellularized blood vessel and said smooth muscle cells migrate to the walls or are present over the middle and outer layers of the decellularized blood vessel.

19. The method of claim 18 , wherein said endothelial cells express VE-cadherein, AcLDL, vWF or CD31.

20. The method of claim 18 , wherein said smooth muscle cells express smooth muscle actin or vimentin.

21. The method of claim 11 , wherein said blood vessel is vein or artery.

Assignments (4)
NAME CHANGE Recorded Apr 22, 2019
From: NOVAHEP AB
To: VERIGRAFT AB
Reel/Frame 048956/0658 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 038758 FRAME 0698. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 16, 2016
From: NOVAHEP AB
To: OLAUSSON - PARTIAL INTEREST (ENTIRE INTEREST OWNED BY NOVAHEP AB, MICHAEL OLAUSSON), MICHAEL
Reel/Frame 039736/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2016
From: NOVAHEP AB
To: OLAUSSON, MICHAEL
Reel/Frame 038758/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2014
From: SUMITRAN-HOLGERSSON, SUCHITRA; OLAUSSON, MICHAEL
To: NOVAHEP AB
Reel/Frame 033994/0942 →
Continuity (2)
Provisional Application 61611810 · Mar 16, 2012
Related Publication 20140377864A1 · Dec 25, 2014